

Electronic Supporting Information

**Production of a promising modular proteinaceous self-assembled delivery system
for vaccination**

*Chao Pan,^{‡a} Jingqin Ye,^{‡a} Sen Zhang,^b Xiang Li,^a Yixin Shi,^a Yan Guo,^a Kangfeng
Wang,^{a,c} Peng Sun,^{a,d} Jun Wu,^{*a} Hengliang Wang^{*a} and Li Zhu^{*a}*

^a State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Biotechnology, Beijing,
100071, PR China

^b State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and
Epidemiology, Academy of Military Medical Sciences, Beijing, 100071, PR China

^c College of Life Science, Hebei University, Baoding, 071002, PR China

^d School of Medicine, Tsinghua University, Beijing, 100084, PR China

*Corresponding author: E-mail: jewly54@bmi.ac.cn, wanghl@bmi.ac.cn, junwu1969@163.com

[‡]These authors contributed equally to this work.






Fig. S1 SDS-PAGE analysis of S-NP that was incubated with or without PNGase F.



27 **Fig. S2** Bio-RBD was analyzed by Coomassie blue staining and western blotting
28 using HRP-labeled streptavidin (SA) after SDS-PAGE separation.
29


30



31

32 **Fig. S3** Analysis of the binding between S-NP and Bio-RBD under different
33 proportions after incubation at 37°C for 1 h by Coomassie blue staining and western
34 blotting (M: marker).

35



36

37 **Fig. S4** RBD and Bio-RBD were separated by SDS-PAGE individually, and then

38 transferred to PVDF membranes. After incubation with S-NP and buffer at 37 °C for

39 one hour, the two membranes were incubated with anti-CTB antibody and

40 HRP-labeled secondary antibody successively to analyze the connection of Biotin and

41 mSA.

42






Fig. S5 S-NP-Bio-RBD was analyzed by DLS.



47 **Fig. S6** Stability analysis of S-NP-Bio-RBD. S-NP-Bio-RBD solution was detected
48 by DLS when incubated at 37 °C for different time periods.

49

50




51

52 **Fig. S7.** Measurement of affinity between ACE2 and RBD, Bio-RBD and
53 S-NP-Bio-RBD by surface plasmon resonance. Different color lines indicate the
54 different concentrations of RBD.

55

56




57

58 **Fig. S8** Cy3-labeled Bio-RBD (Bio-RBD_{Cy3}) was coupled with S-NP
59 (S-NP-Bio-RBD_{Cy3}). Balb/c mice were subcutaneously injected with
60 S-NP-Bio-RBD_{Cy3} or Bio-RBD_{Cy3}, and immunofluorescence was performed to
61 analyze the accumulation of antigen in dLNs 24 h after immunization.

62


63



64

65 **Fig. S9** CD8⁺ T cell counts in dLNs three days after vaccination (n = 3).

66




67

68 **Fig. S10** Immunofluorescence was performed to analyze the formation of germinal
 69 center in dLNs at different time points. Bar = 500 μm.

70

71




72

73 **Fig. S11** Body weight of the mice was measured after immunization with

74 S-NP-Bio-RBD (25 μ g RBD per mouse) for one month.

75



77 **Fig. S12** IgG3 titers against RBD were measured in the serum of Balb/c mice
 78 immunized with S-NP, RBD, Bio-RBD, S-NP+RBD, and S-NP-Bio-RBD after the
 79 third immunization. **** $p < 0.0001$, ns: no significant.

80